Author

Limor Cohen

Primary ORCID profile (0000-0003-1448-0925 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Limor CoheniD3 papers · Howard Hughes Medical Institute

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Anat Bahat Dinur· 1 shared Joshua Ben-Zion· 1 shared Mai Bdarny· 1 shared Manu Prasad· 1 shared Moshe Elkabets· 1 shared Noa Balaban· 1 shared Reidar Grénman· 1 shared

Activity by Year

2018-2018 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anat Bahat Dinur

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The AP-1 complex regulates AXL expression and determines sensitivity to PI3Kα inhibition in esophagus and head and neck squamous cell carcinoma

Mai Bdarny, Manu Prasad, Noa Balaban, Joshua Ben-Zion, Anat Bahat Dinur, Reidar Grénman, Limor Cohen, Moshe Elkabets

This study shows that AP-1 factors regulate AXL expression, which contributes to resistance to PI3Kα inhibition in ESCC and HNSCC, and that JNK inhibition combined with PI3Kα inhibition enhances anti-tumor effects.

bioRxiv · Oct 8, 2018 · PreprintCancer Biology